Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S
Department of Podiatry Services, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Department of Diabetes, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Diabet Med. 2018 Jul;35(7):887-894. doi: 10.1111/dme.13630. Epub 2018 May 10.
To evaluate the feasibility of a one-stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at-risk diabetic foot.
People with diabetes attending retinal screening in hospital and community settings had their feet examined by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10-g monofilament test; and two validated, objective and quick measures of neuropathy obtained using the point-of-care devices 'DPN-Check', a hand-held device that measures sural nerve conduction velocity and amplitude, and 'Sudoscan', a device that measures sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score as the 'gold standard'.
A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10-g monofilament test (14.4%). The prevalence of distal symmetrical polyneuropathy using DPN-check was 51.5% (84.3% sensitivity, 68.3% specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and 61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical polyneuropathy was made in 59 participants (25%), and 56.6% had moderate- or high-risk foot. Participants rated the service very highly.
Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies painful distal symmetrical polyneuropathy and the at-risk foot. Combined large- and small-nerve-fibre assessment using non-invasive, quantitative and quick point-of-care devices may be an effective model for the early diagnosis of distal symmetrical polyneuropathy.
评估一站式微血管筛查服务用于早期诊断糖尿病远端对称性多发性神经病变、疼痛性远端对称性多发性神经病变及糖尿病足高危患者的可行性。
在医院和社区接受视网膜筛查的糖尿病患者由足病医生检查足部。评估内容包括:多伦多临床神经病变评分评估;10克单丝试验;以及使用即时检测设备“DPN-Check”(一种测量腓肠神经传导速度和波幅的手持设备)和“Sudoscan”(一种测量汗腺运动功能的设备)获得的两种经过验证的、客观且快速的神经病变测量方法。以多伦多临床神经病变评分作为“金标准”评估这些设备的诊断效用。
共评估了236名连续参加视网膜筛查服务的患者,其中18.9%的患者此前从未接受过足部检查。使用多伦多临床神经病变评分评估,远端对称性多发性神经病变的患病率为30.9%,10克单丝试验低估了该患病率(14.4%)。使用DPN-check检测远端对称性多发性神经病变的患病率为51.5%(灵敏度84.3%,特异性68.3%),使用Sudoscan足部电化学皮肤传导检测的患病率为38.2%(灵敏度77.4%,特异性68.3%),使用任一结果异常检测的患病率为61.9%(灵敏度93.2%,特异性52.8%)。两种设备的结果均与多伦多临床神经病变评分相关(P<0.001)。59名参与者(25%)被新诊断为疼痛性远端对称性多发性神经病变,56.6%的患者足部为中度或高危。参与者对该服务评价很高。
眼部、足部和肾脏联合筛查可行,接受度高,减少了门诊就诊次数,并能识别疼痛性远端对称性多发性神经病变和足部高危患者。使用非侵入性、定量且快速的即时检测设备联合进行大神经纤维和小神经纤维评估可能是早期诊断远端对称性多发性神经病变的有效模式。